AU2017250300B2 - Porous silicon materials comprising a metal silicate for delivery of therapeutic agents - Google Patents

Porous silicon materials comprising a metal silicate for delivery of therapeutic agents Download PDF

Info

Publication number
AU2017250300B2
AU2017250300B2 AU2017250300A AU2017250300A AU2017250300B2 AU 2017250300 B2 AU2017250300 B2 AU 2017250300B2 AU 2017250300 A AU2017250300 A AU 2017250300A AU 2017250300 A AU2017250300 A AU 2017250300A AU 2017250300 B2 AU2017250300 B2 AU 2017250300B2
Authority
AU
Australia
Prior art keywords
composition
porous silicon
psinp
agent
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017250300A
Other languages
English (en)
Other versions
AU2017250300A1 (en
Inventor
Emily Anglin
Sangeeta Bhatia
Jinmyoung JOO
Jinyoung Kang
Ester KWON
Michael J. Sailor
Matthew SKALAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SPINNAKER BIOSCIENCES Inc
Massachusetts Institute of Technology
University of California San Diego UCSD
Original Assignee
SPINNAKER BIOSCIENCES Inc
Massachusetts Institute of Technology
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SPINNAKER BIOSCIENCES Inc, Massachusetts Institute of Technology, University of California Berkeley, University of California San Diego UCSD filed Critical SPINNAKER BIOSCIENCES Inc
Publication of AU2017250300A1 publication Critical patent/AU2017250300A1/en
Application granted granted Critical
Publication of AU2017250300B2 publication Critical patent/AU2017250300B2/en
Priority to AU2023204322A priority Critical patent/AU2023204322B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Ceramic Engineering (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Preparation (AREA)
AU2017250300A 2016-04-14 2017-04-14 Porous silicon materials comprising a metal silicate for delivery of therapeutic agents Active AU2017250300B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023204322A AU2023204322B2 (en) 2016-04-14 2023-07-05 Porous silicon materials comprising a metal silicate for delivery of therapeutic agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322782P 2016-04-14 2016-04-14
US62/322,782 2016-04-14
PCT/US2017/027772 WO2017181115A1 (en) 2016-04-14 2017-04-14 Porous silicon materials comprising a metal silicate for delivery of therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023204322A Division AU2023204322B2 (en) 2016-04-14 2023-07-05 Porous silicon materials comprising a metal silicate for delivery of therapeutic agents

Publications (2)

Publication Number Publication Date
AU2017250300A1 AU2017250300A1 (en) 2018-11-01
AU2017250300B2 true AU2017250300B2 (en) 2023-04-06

Family

ID=60042009

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017250300A Active AU2017250300B2 (en) 2016-04-14 2017-04-14 Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
AU2023204322A Active AU2023204322B2 (en) 2016-04-14 2023-07-05 Porous silicon materials comprising a metal silicate for delivery of therapeutic agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023204322A Active AU2023204322B2 (en) 2016-04-14 2023-07-05 Porous silicon materials comprising a metal silicate for delivery of therapeutic agents

Country Status (7)

Country Link
US (1) US20210177770A1 (https=)
EP (1) EP3442540A4 (https=)
JP (3) JP7093955B2 (https=)
CN (2) CN114949250A (https=)
AU (2) AU2017250300B2 (https=)
CA (1) CA3021001A1 (https=)
WO (1) WO2017181115A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019191132A1 (en) 2018-03-27 2019-10-03 The Regents Of The University Of California Drug delivery formulations
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
JP7335078B2 (ja) * 2019-02-21 2023-08-29 アサヒグループ食品株式会社 ペプチド含有物を含む組成物の変色抑制方法、並びに粉末組成物、顆粒、及び錠剤
WO2020171680A1 (ko) * 2019-02-22 2020-08-27 주식회사 레모넥스 면역활성 또는 암의 예방 또는 치료용 의약 조성물
GB201904334D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd Carrier system for preparing herbaceous extracts
EP3714879A1 (en) 2019-03-28 2020-09-30 Sisaf Ltd Structured encapsulated silicon-containing particles
GB201904336D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB201904337D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB202110644D0 (en) * 2021-07-23 2021-09-08 Sisaf Ltd Improved nucleic acid vector particles
CN114983977B (zh) * 2022-06-30 2023-03-10 浙江大学 铜-聚多巴胺共修饰的多孔硅颗粒及其制备方法和应用
CN116570721A (zh) * 2023-02-06 2023-08-11 四川农业大学 一种t-705@msn-rvg脑内药物递送载体及其制备方法
CN116510003B (zh) * 2023-06-20 2023-10-20 中国人民解放军军事科学院军事医学研究院 一种负载鼠疫菌rF1-V10蛋白的锰基纳米颗粒疫苗及其在抗鼠疫菌中的应用
WO2025098983A1 (en) * 2023-11-07 2025-05-15 Evonik Operations Gmbh Rna storage and delivery

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011251A1 (en) * 2001-08-01 2003-02-13 Psimedica Limited Pulmonary formulation
WO2005009602A2 (en) * 2003-07-22 2005-02-03 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
US20090068272A1 (en) * 2006-04-25 2009-03-12 Washington State University Mesoporous calcium silicate compositions and methods for synthesis of mesoporous calcium silicate for controlled release of bioactive agents
US20090297441A1 (en) * 2005-09-22 2009-12-03 Leigh Trevor Canham Imaging Agents
US20140336514A1 (en) * 2005-08-05 2014-11-13 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
WO2014201276A1 (en) * 2013-06-12 2014-12-18 The Methodist Hospital Polycation-functionalized nanoporous silicon carrier for systemic delivery of gene silencing agents
WO2015095608A1 (en) * 2013-12-20 2015-06-25 Colgate-Palmolive Company Core shell silica particles and use for malodor reduction

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5194447A (en) 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
JPH07216256A (ja) * 1994-01-28 1995-08-15 Suzuki Yushi Kogyo Kk 着色微粒子とその製造方法
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
DK1419154T3 (da) 2001-08-22 2006-01-09 Wyeth Corp Rapamycin-29-enoler
EP1419153A1 (en) 2001-08-22 2004-05-19 Wyeth Rapamycin dialdehydes
US8765484B2 (en) 2002-02-07 2014-07-01 The Regents Of The University Of California Optically encoded particles
US7433811B2 (en) 2003-05-06 2008-10-07 The Regents Of The University Of California Direct patterning of silicon by photoelectrochemical etching
EP1702414A4 (en) 2003-12-22 2008-04-23 Univ California Office Of The OPTICALLY-CODED PARTICLES WITH GRAY PUMP SPECTROS
AU2004308380A1 (en) 2003-12-22 2005-07-14 The Regents Of The University Of California Optically encoded particles, system and high-throughput screening
ES2669585T3 (es) 2004-10-29 2018-05-28 The Regents Of The University Of California Micropartículas porosas de silicio para la entrega de fármaco para el ojo
KR20160021307A (ko) 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
WO2010129545A2 (en) 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles
AU2012249474A1 (en) * 2011-04-28 2013-11-07 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
EP2739937B1 (en) * 2011-08-02 2023-03-01 The Regents of The University of California Rapid, massively parallel single-cell drug response measurements via live cell interferometry
BR112014006596A2 (pt) 2011-09-21 2017-03-28 Yissum Res Dev Co nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas
EP2765997A4 (en) * 2011-10-14 2015-06-24 Stc Unm POROUS NANOPARTICLE-SUPPORTED LIPID DOUBLE LAYERS (PROTOCOLS) FOR THE TARGETED RELEASE BY TRANSDERMAL RELEASE AND USE METHOD THEREFOR
CN102552972A (zh) 2011-12-22 2012-07-11 南京工业大学 金属离子修饰介孔氧化硅及其制备方法
US20160002272A1 (en) 2013-02-25 2016-01-07 The Regents Of The University Of California Surface functionalized porous silicon material and method of making thereof
MX354968B (es) * 2013-12-20 2018-03-27 Colgate Palmolive Co Producto para el cuidado oral con blanqueador dental con particulas de silice de nucleo cubierto.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011251A1 (en) * 2001-08-01 2003-02-13 Psimedica Limited Pulmonary formulation
WO2005009602A2 (en) * 2003-07-22 2005-02-03 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
US20140336514A1 (en) * 2005-08-05 2014-11-13 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
US20090297441A1 (en) * 2005-09-22 2009-12-03 Leigh Trevor Canham Imaging Agents
US20090068272A1 (en) * 2006-04-25 2009-03-12 Washington State University Mesoporous calcium silicate compositions and methods for synthesis of mesoporous calcium silicate for controlled release of bioactive agents
WO2014201276A1 (en) * 2013-06-12 2014-12-18 The Methodist Hospital Polycation-functionalized nanoporous silicon carrier for systemic delivery of gene silencing agents
WO2015095608A1 (en) * 2013-12-20 2015-06-25 Colgate-Palmolive Company Core shell silica particles and use for malodor reduction

Also Published As

Publication number Publication date
JP7093955B2 (ja) 2022-07-01
AU2023204322B2 (en) 2025-08-21
AU2017250300A1 (en) 2018-11-01
JP2024094359A (ja) 2024-07-09
WO2017181115A1 (en) 2017-10-19
EP3442540A4 (en) 2019-12-18
AU2023204322A1 (en) 2023-07-27
JP2019511582A (ja) 2019-04-25
US20210177770A1 (en) 2021-06-17
CN114949250A (zh) 2022-08-30
CN109843301B (zh) 2022-05-27
CN109843301A (zh) 2019-06-04
CA3021001A1 (en) 2017-10-19
JP2022121463A (ja) 2022-08-19
EP3442540A1 (en) 2019-02-20

Similar Documents

Publication Publication Date Title
AU2023204322B2 (en) Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
Hu et al. Layered double hydroxide-based nanomaterials for biomedical applications
Joo et al. Porous silicon–graphene oxide core–shell nanoparticles for targeted delivery of siRNA to the injured brain
Yan et al. Layered double hydroxide nanostructures and nanocomposites for biomedical applications
Cai et al. Biodegradable inorganic nanostructured biomaterials for drug delivery
Sayed et al. Porous inorganic drug delivery systems—a review
Wang et al. Facile synthesis of uniform virus-like mesoporous silica nanoparticles for enhanced cellular internalization
Zhou et al. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors
Zou et al. Programmed packaging of mesoporous silica nanocarriers for matrix metalloprotease 2-triggered tumor targeting and release
Perez et al. Silica-based multifunctional nanodelivery systems toward regenerative medicine
Sokolova et al. Inorganic nanoparticles as carriers of nucleic acids into cells
Yang et al. Near-infrared light-activated cancer cell targeting and drug delivery with aptamer-modified nanostructures
Gao et al. H 2 O 2-responsive and plaque-penetrating nanoplatform for mTOR gene silencing with robust anti-atherosclerosis efficacy
Bouladjine et al. New advances in nanocrystalline apatite colloids intended for cellular drug delivery
JP2019526626A (ja) 皮膚処置のためのイオン種に基づく局所処方物
Huang et al. Ca 2+ participating self-assembly of an apoferritin nanostructure for nucleic acid drug delivery
Choi et al. Calcium-doped mesoporous silica nanoparticles as a lysosomolytic nanocarrier for amine-free loading and cytosolic delivery of siRNA
KR20140096876A (ko) 표면 아민화 메조다공성 생체활성유리 나노입자, 이의 제조방법 및 이를 포함하는 생체분자 전달체 조성물
Yang et al. CaCO 3 nanoplatform for cancer treatment: drug delivery and combination therapy
Wang et al. Co-delivery of PLK1-specific shRNA and doxorubicin via core-crosslinked pH-sensitive and redox ultra-sensitive micelles for glioma therapy
Avitabile et al. Recent Cutting‐Edge Technologies for the Delivery of Peptide Nucleic Acid
WO2018162676A1 (en) DISINTEGRATABLE POROUS ORGANOSILICA OR ORGANOMETALOXIDE NANOPARTICLES AND USES THEREOF AS VEHICLE FOR CONTROLLED DELIVERY OF siRNA
US20220135978A1 (en) Anti-mirna carrier conjugated with a peptide binding to a cancer cell surface protein and use thereof
Rana et al. Porous silica nanoparticles for targeted bio-imaging and drug delivery applications
SG11202109703WA (en) A peptide for the delivery of anionic materials

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)